STOML2 interacts with PHB to activate the MEK/ERK signaling pathway and mediates autophagy‑related proteins in the progression of hepatocellular carcinoma
International Journal of Molecular Medicine · 2025
DOI: 10.3892/ijmm.2025.5709 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Medicine, 2025. Verfasst von Haoyang Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Hepatobiliary and Pancreatic Surgery, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei 0630…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, MAP Kinase Signaling System, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) treatment remains challenging due to the prevalence of metastasis and chemotherapy resistance. Mitochondrial stomatin‑like protein 2 (STOML2), which is upregulated in various solid tumors, is associated with a poor prognosis; however, its biological function and molecular mechanism in HCC remain unclear. The present study aimed to elucidate the oncogenic mechanism of STOML2 in HCC and to explore its potential as a therapeutic target. Firstly, STOML2 expression in HCC and matched normal liver tissues was analyzed. In addition, STOML2‑knockdown (HCCLM3‑short hairpin RNA‑STOML2) and ‑overexpression (Huh7‑STOML2) cell models were established. Wound healing, Cell Counting Kit‑8 and Transwell assays, and flow cytometry were performed to assess cell proliferation, invasion, migration and apoptosis in vitro. Furthermore, the biological function of STOML2 was confirmed in vivo. Co‑immunoprecipitation (co‑IP) and immunofluorescence staining were conducted to validate the interaction of STOML2 with prohibitin (PHB) following the prediction of binding partners. Downstream pathways regulated by STOML2 were identified using western blotting and were further investigated using the RAF1 inhibitor sorafenib. The present study revealed that STOML2 expression was significantly upregulated in HCC tissues and metastatic lesions, and was associated with poor patient prognosis. The in vitro experiments showed that STOML2 overexpression promoted proliferation, invasion, migration and autophagy, while inhibiting apoptosis in Huh7 cells. Conversely, STOML2 knockdown reversed these phenotypic changes. Furthermore, co‑IP confirmed the direct interaction between STOML2 and PHB, which activated the RAF/MEK/ERK signaling pathway. The in vivo experiments further confirmed that STOML2 overexpression significantly accelerated tumor growth, whereas STOML2 or PHB knockdown inhibited tumor progression. In addition, sorafenib treatment suppressed STOML2‑mediated cell migration and the expression of autophagy‑related proteins by blocking the MAPK pathway. These findings elucidated the molecular mechanism by which STOML2 promotes the malignant progression of HCC and demonstrated that targeted inhibition of the PHB‑MAPK pathway may reverse the pro‑tumorigenic effects of STOML2. STOML2 may serve as both a prognostic biomarker and a therapeutic target in HCC. The current study provides a theoretical foundation for individualized treatment in patients with HCC and high STOML2 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Department of Hepatobiliary and Pancreatic Surgery, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei 063000, P.R. China.
- Department of Urology, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei 063000, P.R. China.
- Laboratory Animal Center, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China.
Zitieren
APA
Hu, H., Zhang, H., Han, S., Chen, J., & Xie, Y. (2025). STOML2 interacts with PHB to activate the MEK/ERK signaling pathway and mediates autophagy‑related proteins in the progression of hepatocellular carcinoma. International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2025.5709
Vancouver
Hu H, Zhang H, Han S, Chen J, Xie Y. STOML2 interacts with PHB to activate the MEK/ERK signaling pathway and mediates autophagy‑related proteins in the progression of hepatocellular carcinoma. International Journal of Molecular Medicine. 2025. doi:10.3892/ijmm.2025.5709
BibTeX
@article{Hu2025,
author = {Hu, Haoyang and Zhang, Haozhe and Han, Shuai and Chen, Jianli and Xie, Ying},
title = {STOML2 interacts with PHB to activate the MEK/ERK signaling pathway and mediates autophagy‑related proteins in the progression of hepatocellular carcinoma},
journal = {International Journal of Molecular Medicine},
year = {2025},
doi = {10.3892/ijmm.2025.5709}
}
EUVIMED